Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
The European Commission on Friday approved the acquisition of control over Andreae-NorisZahn AG (Anzag; ANZG: DE), one of Germany's largest drug wholesalers, by the international group Alliance Boots. The Commission concluded that the transaction would not significantly impede effective competition in the European Economic Area (EEA) or any substantial part of it. 20 December 2010
Pharmaceutical
In the now nearly five month saga, Cypress Biosciences (Nasdaq CYPB) has done an about turn and accepted the takeover offer from hedge fund Ramius' firm Ramius V&O Acquisitions arm and Royalty Pharma, albeit at an even higher price. The news saw Cypress' shares leap 12% to $6.47 in afternoon US trading yesterday. 16 December 2010
Pharmaceutical
Ending a long struggle to gain 100% control of eye care specialist Alcon (NYSE: ACL), Swiss drug major Novartis (NOVN: VX) has announced a final agreement in the price at which it will purchase the Alcon minority stake. 15 December 2010
Pharmaceutical
Analysts at US financial services group Zacks Investment Research have issued a note reviewing UK drug giant GlaxoSmithKline's (LSE: GSK) recent buying spree, pointing first to its plans to acquire UK-based Maxinutrition Group for a cash payment of about 162 million ($258 million). The deal includes the repayment of outstanding debt. 15 December 2010
Pharmaceutical
Luitpold Pharmaceuticals, a New York, USA-based subsidiary of Japanese drug major Daiichi Sankyo (TKO: 4568), has signed a binding merger agreement with privately-held Roxro Pharma, a US specialty pharmaceutical company developing products for the treatment of acute pain conditions. Financial terms of the deal were not disclosed. 14 December 2010
Pharmaceutical
Aiming to resolve a long-running dispute relating to the rabies vaccine Rabipur, French drug major Sanofi-Aventis' (Euronext: SAN) Aventis Pharma has agreed to sell its 49% equity holding in India-based Chiron Behring Vaccines Pvt Ltd (CBVPL) to Swiss major Novartis (NOVN: VX), for a consideration of around $22.4 million. The transaction is expected to close before year end. 14 December 2010
Pharmaceutical
Uppsala, Sweden-based privately held Phadia says that it has entered into an agreement to acquire 100% of the shares in the Chinese marketing company WKL from the parent company MeiRui. Financial terms were not disclosed, but the transaction is expected to complete by the end of 2010, and is subject to regulatory approval. 14 December 2010
Pharmaceutical
Following rumor and speculation over the weekend, this morning German drug major Merck KGaA (MRK: DE) announced that Stefan Oschmann will become a member of the executive board and general partner of the company, succeeding Elmar Schnee, who leaves 'for personal reasons.' 13 December 2010
Pharmaceutical
Big Pharma has had an active 2010, with a 20% increase in the number of deals concluded compared to last year according to latest figures released by MedTRACK, the biomedical database from Life Science Analytics. The 'deals' include both licensing and merger and acquisition activities. 10 December 2010
Pharmaceutical
US health care giant Johnson & Johnson (NYSE: JNJ) is making a recommended cash offer for all of the issued and outstanding ordinary shares Netherlands-based vaccine maker Crucell NV (Euronext: CRXC), at the previously-announced price of 24.75 euros a share, to take full control of the company of which it already owns 17.9% (The Pharma Letter September 17). That means J&J will pay 1.75 billion euros ($2.3 billion) for the balance of the shares. 9 December 2010
Pharmaceutical
Confirming earlier speculation of a buy in China (The Pharma Letter December 2), UK drugs giant GlaxoSmithKline (LSE: GSK) yesterday announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma for a cash consideration of around $70 million. 8 December 2010
Pharmaceutical
San Diego, USA-based Cytori Therapeutics (Nasdaq: CYTX) and Japan's Astellas Pharma (4503: JP) have entered into a strategic equity agreement to evaluate the potential of adipose derived stem and regenerative cells for the treatment of serious illnesses for which there is no fundamental treatment. The news sent the US firm's shares up 17% to $6.08 in pre-market trading yesterday. 8 December 2010
Pharmaceutical
US drug giant Merck & Co (NYSE: MRK) says it has entered into a definitive agreement under which it will acquire SmartCells, a private company developing a glucose responsive insulin formulation for the treatment of diabetes mellitus, that could eventually earn the latter more than $500 million. 3 December 2010
Pharmaceutical
As part of its ongoing efforts to ensure competition in US health care markets, the Federal Trade Commission has challenged Laboratory Corporation of America's (NYSE: LH) $57.5 million acquisition of rival clinical laboratory testing company Westcliff Medical Laboratories, which was completed in June this year, alleging that the transaction would harm competition in Southern California. 3 December 2010
Pharmaceutical
Dutch specialty pharmaceutical company, Eurand NV (Nasdaq: EURX) has agreed to be acquired by privately-held US firm Axcan Holdings, which is focused on the treatment of gastrointestinal disorders, for $12.00 per share in cash, a premium of 9.4% on its Tuesday closing price. The fully diluted equity value of the transaction is approximately $583 million. Eurand's shares rose 8.3% to $11.87 in morning trading on Wednesday. 2 December 2010
Pharmaceutical
Shanghai Pharmaceutical Holding, China's second-largest drug company by revenue, said on Tuesday that it plans to acquire a 55.45% stake in China Health System, as part of its efforts to tap into the country's northern market, reports the People's Daily newspaper, in what looks to be the biggest acquisition in China's drug distribution sector. 2 December 2010
Pharmaceutical
USA headquartered Cardinal Health (NYSE: CAH) yesterday completed the $470 million acquisition of privately-held Zuellig Pharma China, a leading health care distribution business in China, known locally as Yong Yu, and the largest pharmaceutical importer in the country. The transaction extends Cardinal Health's distribution and services presence into one of the world's fastest growing health care markets and provides a platform to drive long-term growth, the company says. 30 November 2010
Pharmaceutical
UK pharmaceutical giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it will increase its shareholding in US respiratory drug partner Theravance (Nasdaq: THRX) through the purchase of common stock in a private placement. 30 November 2010
Pharmaceutical
According to a filing with the Hong Kong Stock Exchange, Sihuan Pharmaceutical, the second-largest cardio-cerebral vascular drugmaker in China, plans to acquire Dupromise Holdings for as much as 2.4 billion renminbi ($360.72 million), via its wholly-owned SunMoral International, reports China Knowledge Online. 29 November 2010
Pharmaceutical
Global drugs behemoth Pfizer (NYSE: PFE) has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals (NYSE: KG) for $14.25 per share, or around $3.6 billion, announced last month and aimed at expanding its presence in the pain relief market (The Pharma Letter October 13). 23 November 2010
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze